Miyarisan Pharmaceutical Co., Ltd.

Overview

Miyarisan Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company specializing in the research, development, manufacturing, and sales of Clostridium butyricum MIYAIRI. The company is dedicated to contributing to the healthy and prosperous lives of people and animals worldwide through its innovative products and services. Their portfolio includes ethical pharmaceuticals, over-the-counter medicines, veterinary medicines, and feed additives. In January 2023, Miyarisan Pharmaceutical partnered with CHAIN Biotechnology, a UK-based biotech firm, to accelerate the development of live biotherapeutics. This strategic investment aims to co-develop and manufacture novel oral treatments targeting infections and cancer, leveraging Miyarisan's expertise in Clostridium bacterial spore manufacturing and fermentation process development. The collaboration focuses on repurposing a proven Clostridium probiotic species into a therapeutic, utilizing CHAIN's Clostridium Assisted Drug Delivery (CADD) platform. Miyarisan Pharmaceutical's investment philosophy centers on enhancing the microbiome to improve health. By combining CHAIN's innovative genetic engineering with Miyarisan's manufacturing capabilities, the partnership seeks to develop new and improved medicines, addressing a range of immune-oncological and infective targets. This approach reflects Miyarisan's commitment to advancing therapeutic platforms that contribute to global health and well-being.

Investment Focus

• Focus on therapeutic platforms
• Alignment with microbiome enhancement
• Potential for global health impact

Portfolio Companies